Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This randomized controlled trial compares two regimens of topical therapy:
- tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four times/day
- combination of tobramycin 0.3% - dexamethasone 0.1% (TobraDex®, Alcon), one drop four
times/day, plus Ketorolac tromethamine 0.5% (Acular®, Allergan), one drop three
times/day. The topical treatment is administered for 28 days after phacoemulsification.
Patients are independently assessed by two ophthalmologists. On day 28, patients are
evaluated for
- corneal edema
- conjunctival redness
- anterior chamber reaction. Moreover, the cases necessitating continuation of treatment
are compared in the two groups on day 28 and 42.